Daily Respiratory Research Analysis
Across critical and chronic respiratory care, three studies stand out: mechanical power during the first 24 hours of ventilation independently predicts ICU mortality in acute hypoxemic respiratory failure; timely spirometry at treatment initiation in obstructive disease is linked with substantially lower mortality; and simple ABG-derived Met-Hb/CO-Hb thresholds during VV-ECMO predict hemolysis and ICU mortality in ARDS. These findings emphasize actionable metrics and diagnostics that can be impl
Summary
Across critical and chronic respiratory care, three studies stand out: mechanical power during the first 24 hours of ventilation independently predicts ICU mortality in acute hypoxemic respiratory failure; timely spirometry at treatment initiation in obstructive disease is linked with substantially lower mortality; and simple ABG-derived Met-Hb/CO-Hb thresholds during VV-ECMO predict hemolysis and ICU mortality in ARDS. These findings emphasize actionable metrics and diagnostics that can be implemented immediately to improve outcomes.
Research Themes
- Early ventilator energy load (mechanical power) as a modifiable mortality risk in AHRF
- Diagnostic quality and outcomes: timely spirometry in obstructive airway disease
- Low-cost, real-time biomarkers (Met-Hb/CO-Hb) for hemolysis and risk stratification during VV-ECMO
Selected Articles
1. The Association Between Mechanical Power Within the First 24 Hours and ICU Mortality in Mechanically Ventilated Adult Patients With Acute Hypoxemic Respiratory Failure: A Registry-Based Cohort Study.
In a multicenter cohort of 9,031 AHRF patients, higher mechanical power (>17 J/min) during the first 24 hours of IMV was independently associated with increased ICU mortality, fewer ventilator-free days, and lower extubation rates. The dose-response was nonlinear and no consistent safe threshold emerged, suggesting early MP minimization may be beneficial.
Impact: Mechanical power is a modifiable, integrative ventilator metric; showing strong, early association with mortality across AHRF can shift bedside targets beyond traditional tidal volume and pressure settings.
Clinical Implications: At IMV initiation, consider strategies that reduce mechanical power (eg, lower driving pressure/respiratory rate, optimized PEEP, avoiding excessive flow and volume) while maintaining gas exchange. MP can serve as an early risk marker to guide ventilator titration and trial enrollment.
Key Findings
- High mechanical power (>17 J/min) within 24 hours was associated with higher ICU mortality (adjusted OR 1.58; 95% CI 1.44–1.72).
- Nonlinear dose-response without a consistent safe threshold; higher MP linked to lower extubation rates and fewer ventilator-free days.
- Robust findings using IPTW-adjusted multivariable models and spline analyses across a large multicenter cohort.
Methodological Strengths
- Large multicenter registry with 9,031 AHRF patients and prespecified exclusion of prolonged pre-inclusion ventilation.
- Advanced causal modeling (IPTW), multivariable adjustment, and restricted cubic spline analysis for nonlinear effects.
Limitations
- Observational design with potential residual confounding and center-level practice variability.
- Mechanical power derived using dynamic driving pressure; measurement error and component attribution cannot be fully disentangled.
Future Directions: Prospective interventional trials targeting early mechanical power reduction should test causality and define practical bundles for safe MP minimization across AHRF phenotypes.
BACKGROUND: Despite the widespread adoption of lung-protective ventilation strategies, mortality among patients receiving invasive mechanical ventilation (IMV) remains high. Mechanical power (MP) integrates various variables responsible for ventilator-induced lung injury and has been associated with mortality in patients with ARDS. However, the impact of MP on ICU mortality in the larger group of patients with acute hypoxemic respiratory failure (AHRF) has not been well established, and previous studies have reported inconsistent thresholds for predicting outcomes. RESEARCH QUESTION: Is high MP (> 17 J/min) within the first 24 hours of IMV, calculated using dynamic driving pressure, associated with ICU mortality in patients with AHRF? Additionally, does a threshold exist below which IMV is considered safe? STUDY DESIGN AND METHODS: In this multicenter cohort study, we included adult patients with AHRF who received IMV. Patients were excluded if they received IMV for > 24 hours before inclusion or were receiving extracorporeal life support. We applied multivariable logistic regression models with inverse probability of treatment weighting and used change-point regression models with restricted cubic splines. RESULTS: Of the 21,714 patients in our registry, 9,031 patients (42%) met the inclusion criteria. After adjusting for baseline characteristics, high MP was associated with increased ICU mortality (OR, 1.58; 95% CI, 1.44-1.72), with a nonlinear dose-response relationship. No consistent safe MP threshold was identified. High MP also was associated with lower extubation rates and fewer ventilator-free days. INTERPRETATION: In this study, exposure to high MP within the first 24 hours of IMV was associated with increased ICU mortality in patients with AHRF. The absence of a consistent safe threshold suggests that reducing MP at IMV initiation may be a strategy to improve outcomes, warranting exploration in clinical trials.
2. Association of Timely Spirometry With Lower All-Cause Mortality: A Nationwide Obstructive Cohort Study.
In 146,205 Belgian adults starting chronic respiratory treatment, only 20.9% had spirometry at initiation. Timely spirometry was associated with a 34% lower all-cause mortality risk and reduced short-acting bronchodilator use; underuse was most pronounced in primary care and among women, the very young/old, cognitively impaired, and frail.
Impact: Demonstrates a strong outcome signal linking diagnostic quality to survival at a national scale and identifies inequities, supporting policy and quality-improvement interventions in airway disease care.
Clinical Implications: Prioritize spirometry at treatment initiation for suspected obstructive disease, especially in primary care and vulnerable populations. Embed spirometry access (equipment, training, workflows) and audit timely testing as a quality metric.
Key Findings
- Only 20.9% received spirometry at treatment initiation; 13.8% received it during follow-up.
- Timely spirometry was associated with 34% lower all-cause mortality (aHR 0.66; 95% CI 0.63–0.70) and lower SABA use.
- Underuse concentrated in primary care; women, age <60 or >80, cognitive impairment, frailty, and low SES were less likely to be tested.
Methodological Strengths
- Nationwide cohort with 146,205 incident treatment initiators and linkage to outcomes.
- Robust multivariable logistic, Cox, and competing risk (Fine-Gray) models to evaluate testing and survival.
Limitations
- Administrative data may lack clinical granularity (symptom burden, spirometric values).
- Residual confounding and indication bias cannot be fully excluded.
Future Directions: Implement and evaluate system-level interventions that increase timely spirometry, with stratified analyses to reduce disparities and test impact on treatment appropriateness and survival.
BACKGROUND: Although spirometry is the gold standard for diagnosing COPD, it is underused in clinical practice. RESEARCH QUESTION: Which factors are associated with timely spirometry (at chronic treatment initiation) in a clinically relevant population of people starting chronic treatment for respiratory symptoms? Is this diagnostic test associated with lower mortality risk? STUDY DESIGN AND METHODS: Incident adult users of chronic respiratory medication were identified in Belgian nationwide data. The odds on timely spirometry were examined by multivariable logistic regression and impact on survival by using multivariable Cox regression analysis. In those patients not receiving timely spirometry, factors related to further delay in spirometry were analyzed with a multivariable Fine-Gray subdistribution hazard regression. RESULTS: Among 146,205 chronic treatment initiators, 20.9% had spirometry at treatment initiation, and 13.8% received spirometry during follow-up. Although primary care physicians prescribed 81.1% of initiated treatments, general practitioners performed only 5.1% of all spirometry tests. People who received spirometry at treatment initiation had a 34% lower mortality risk (adjusted hazard ratio, 0.66; 95% CI, 0.63-0.70) and had less use of short-acting bronchodilators. Smoking, respiratory morbidities, and congestive heart failure increased chance of spirometry use. In contrast, female sex, age < 60 years or > 80 years, cognitive impairment, and frailty lowered the chance of spirometry use, both at initiation and during follow-up. Low socioeconomic status, depression/anxiety, and antibiotic use were associated with a lower chance of spirometry use at treatment initiation, whereas during follow-up, antibiotic use was associated with a higher chance of spirometry over time. In addition, anemia and cachexia were associated with a lower chance of spirometry use during follow-up. INTERPRETATION: Only 1 in 3 initiators of chronic treatment for obstructive lung disease underwent spirometry. Spirometry was particularly underused in primary care. Especially (never-smoking) female participants and vulnerable patients may be at increased risk for underdiagnosis and suboptimal treatment. Importantly, spirometry at treatment initiation was significantly associated with better prognosis, possibly through better-tailored care.
3. Carboxyhemoglobin and Methemoglobin as Biomarkers of Hemolysis and Mortality in Acute Respiratory Distress Syndrome Treated by Veno-Venous Extracorporeal Membrane Oxygenation.
In 435 ARDS patients on VV-ECMO, routinely available ABG-derived Met-Hb and CO-Hb were independently associated with hemolysis and ICU mortality. Practical cutoffs (Met-Hb ≥1.25% and CO-Hb ≥2%) provided clinically useful risk stratification with an AUC of 0.803 for mortality modeling.
Impact: Introduces low-cost, continuously accessible biomarkers to flag hemolysis and mortality risk during ECMO, potentially enabling earlier circuit or management interventions without specialized assays.
Clinical Implications: In VV-ECMO for ARDS, track mean Met-Hb and CO-Hb; consider thresholds (Met-Hb ≥1.25%, CO-Hb ≥2%) to prompt evaluation for hemolysis (circuit inspection, hemolysis labs) and escalate monitoring or therapy in high-risk patients.
Key Findings
- Met-Hb independently associated with hemolytic events (adjusted OR 2.99; 95% CI 2.19–4.10); 1.55% gave 90% specificity for hemolysis.
- Mean CO-Hb (OR 2.03; 95% CI 1.60–2.61) and Met-Hb (OR 2.78; 95% CI 1.59–5.09) associated with ICU mortality; mortality cutoffs: CO-Hb 2%, Met-Hb 1.25%.
- Mortality model including mCO-Hb and mMet-Hb achieved AUC 0.803.
Methodological Strengths
- Moderate-to-large single-center cohort (n=435) with multivariable modeling and recursive partitioning for clinically actionable cutoffs.
- Use of routinely measured ABG parameters enhances real-world applicability.
Limitations
- Single-center retrospective design; external validity and causality are limited.
- Potential confounding by disease severity, circuit type, and co-interventions not fully accounted for.
Future Directions: Prospective multicenter validation of Met-Hb/CO-Hb thresholds, integration into ECMO hemolysis bundles, and testing whether threshold-triggered interventions improve outcomes.
BACKGROUND: Critically ill patients who receive circulatory or respiratory assist using extracorporeal membrane oxygenation (ECMO) may develop hemolysis, which can complicate the delivery of supportive care and be a potential risk factor for increased morbidity and mortality. Clinically, hemolysis is often identified using laboratory markers such as cell-free hemoglobin (CFH) and haptoglobin (Hp). However, such measurements require photometry or enzyme-linked immunosorbent assay (ELISA) and are labor intensive. In contrast, metabolic downstream products of CFH, such as carboxyhemoglobin (CO-Hb) and methemoglobin (Met-Hb), can be regularly monitored via arterial blood gas analyses in the intensive care unit (ICU). We hypothesized that CO-Hb and Met-Hb values measured during ECMO would correlate with the presence of hemolytic events as measured by CFH values exceeding 50mg/dl. We further hypothesized that CO-Hb and Met-Hb levels would correlate with peri-ECMO mortality. METHODS: Retrospective analysis of 435 patients with acute respiratory distress syndrome (ARDS) and veno-venous ECMO admitted to a tertiary ARDS referral center. Plasma concentrations of CO-Hb and Met-Hb were correlated with hemolytic events. Cutoff values of mean CO-Hb (mCO-Hb) and mean Met-Hb (mMet-Hb) associated with increased ICU mortality were calculated with recursive binary partitioning. Single and multivariable regression models for HE and ICU mortality were trained and compared. RESULTS: Simple and multivariable models including potential confounders identified associations between Met-Hb and hemolytic events (adj. odds ratio [OR] 2.99 [95% confidence interval {CI}, 2.19-4.10], P < .001). A cutoff value with 90% specificity of a hemolytic event was estimated for Met-Hb (1.55%). Both, mean CO-Hb (OR 2.03 [95% CI, 1.60-2.61], P < .001) and Met-Hb (2.78 [1.59-5.09], P < .001) were associated with ICU mortality. Cutoff values for mortality were 2% for mean CO-Hb and 1.25% for mean Met-Hb. The multivariable regression model for mortality including the continuous markers mCO-Hb and mMet-Hb produced an area under the curve (AUC) of 0.803. CONCLUSIONS: In patients with ARDS and ECMO, Met-Hb plasma concentrations were independently associated with hemolytic events. Both, mean CO-Hb and Met-Hb levels were associated with ICU mortality. These markers and their associated cutoff values might serve as a risk indicator in clinical practice.